|
This deal falls into the wider pipeline restocking trend in pharma, as companies look to protect their revenue amid looming patent expirations.
|
 |
|
This partnership meshes with OBT’s hybrid partnership-pipeline strategy, which prioritises collaboration to extend its market impact.
|
|
|
Replimune’s RP1 is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.
|
|
|
Standard of care HNSCC regimens with curative intent demand surgery, radiation, and chemotherapy - treatments that many patients cannot tolerate.
|
|
|
C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.
|
|
|
Kelly Parliament, staff application scientist at Beckman Coulter Life Sciences, discusses how automation is improving the efficiency of single-cell transcriptomic workflows.
|
|
|
The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.
|
|
|
Gan & Lee will receive a $5m upfront payment plus up to $76.1m in milestone payments.
|
|
